Page last updated: 2024-12-07

5-propynyluracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-propynyluracil: a PYaraU metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131813
CHEMBL ID4642216
SCHEMBL ID13296
MeSH IDM0221579

Synonyms (19)

Synonym
unii-90ni1zdq6n
134700-29-1
90ni1zdq6n ,
2,4(1h,3h)-pyrimidinedione, 5-(1-propynyl)-
5-pu
5-prop-1-ynyl-1h-pyrimidine-2,4-dione
5-propynyluracil
SCHEMBL13296
UJBCLAXPPIDQEE-UHFFFAOYSA-N
5-(1-propynyl)uracil
DTXSID10158869
2,4(1h,3h)-pyrimidinedione,5-(1-propyn-1-yl)-
FT-0713422
Q27271337
BS-47624
5-(prop-1-yn-1-yl)pyrimidine-2,4(1h,3h)-dione
CHEMBL4642216
CS-0436837
F77583

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Netivudine dosing produces complete inhibition of plasma dihydropyrimidine dehydrogenase."( Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine.
Callaghan, J; Crome, P; Fraser, I; Frick, L; Peck, R; Posner, J; Wiggs, R; Wootton, R, 1996
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1664571Antitubercular activity against Mycobacterium tuberculosis H37Ra assessed as bacterial growth inhibition by MABA relative to control2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1664575Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1664574Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1664579Antitubercular activity against Mycobacterium bovis BCG assessed as bacterial growth inhibition by MABA relative to control2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
AID1664576Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
The synthesis and antituberculosis activity of 5-alkynyl uracil derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]